Yan Wen

Yan Wen

Auto-generated profile, based on publicly available information

Yan Wen

Beijing Tropical Medicine Research Institute, Beijing Friendship Hospital, Capital Medical University, Beijing, China

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2013 in The American Journal of Tropical Medicine and Hygiene
Verified
Journal Article
Closed access
YWYan Wen
Yan Wen
HLHuan-Ying Li
Huan-Ying Li
JLJian Liu
Jian Liu
YZYing Zhang
Ying Zhang
YXYan Xing
Yan Xing
LYLian-Chao Yuan
Lian-Chao Yuan
We evaluated the sensitivity and specificity of a nested-polymerase chain reaction (PCR) method for detection of Mycobacterium leprae DNA from whole blood. Whole-blood specimens were subjected to nested-PCR amplification of M. leprae repeat DNA sequences in 49 multibacillary (MB) and 30 paucibacillary (PB) leprosy patients, 96 household contacts (HHCs), 18 tuberculosis (TB) patients, and 35 normal healthy individuals. M. leprae DNA was detected in 95.92% (47/49) of MB, 70% (21/30) of PB, and 6.25% (6/96) of HHC, but it was not detected in 18 TB or 35 normal controls. The sensitivities of the anti-bovine serum albumin (ND-O-BSA) immunoglobulin M (IgM) and antifusion protein of ML0405-ML2331 IgG for MB were 97.96% and 89.8%, and these values for PB were 70% and 53.33%. However, the ND-O-BSA enzyme-linked immunosorbent assay (ELISA) had lower specificity, with relatively high false-positive results for TB patients (16.67%) and normal healthy controls (10%). Based on these promising findings, we propose the use of nested PCR of whole-blood samples along with ELISA test for early detection of leprosy cases.

27 December 2019 in PLOS Neglected Tropical Diseases
Verified
Journal Article
Open access
PDF file
XCXiaohua Chen
Xiaohua Chen
JHJun He
Jun He
JLJian Liu
Jian Liu
YYYuangang You
Yuangang You
LYLianchao Yuan
Lianchao Yuan
YWYan Wen
Yan Wen
Although leprosy is efficiently treated by multidrug therapy, resistance to first-line (dapsone, rifampin) and second-line (fluoroquinolones) drugs has been described worldwide. However, the characteristics of drug resistance in Southwest China remain unknown. Furthermore, the sensitivity of polymerase chain reaction (PCR)/sequencing for resistance detection is limited, especially for paucibacillary (PB) leprosy patients. The current study aimed to develop a nested PCR/sequencing and TaqMan SNP Genotyping Assay to increase the sensitivity of the method used to detect drug resistance in Mycobacterium leprae and to reveal the nature of M. leprae drug resistance in Southwest China. Seventy-six specimens, including skin biopsy (n = 64), formalin-fixed paraffin-embedded (FFPE) (n = 11) and skin-slit smear (SSS) (n = 1) samples from multibacillary (MB, n = 70) and PB (n = 6) leprosy patients from Southwest China, were included in this study. The presence of mutations in drug resistance-determining regions (DRDRs) of the rpoB, folP1, and gyrA genes, which are associated with rifampicin, dapsone, and quinolone resistance, respectively, was detected by PCR/sequencing, as recommended by the WHO, and the nested PCR and TaqMan SNP Genotyping Assay developed in this study. Mutations in the folP gene were detected in 19 (25.00%) samples, indicating dapsone-resistant M. leprae, with one (1.31%) sample showing mutations in two genes, folP and gyrA, reflecting multidrug-resistant strains to dapsone and ofloxacin. However, no rpoB mutation was detected. Compared with PCR/sequencing, nested PCR increased the sensitivity of detecting rpoB (from 51.39% to 78.94% for leprosy patients and from 0.00% to 50.00% for PB), gyrA (from 75.00% to 80.26% for leprosy patients and from 50.00% to 66.67% for PB), and folP1 (from 5.26% to 84.21% for leprosy patients and from 0.00% to 66.67% for PB). Moreover, the TaqMan SNP Genotyping Assay showed greater sensitivity for folP1 detection (from 5.26% to 78.94–86.84% for leprosy patients and from 0.00% to 33.33%-83.33% for PB patients) than the PCR/sequencing method. In addition, the latter method was able to more easily distinguish heterozygous genotypes and mutant homozygous genotypes from homozygous genotypes. Nested PCR/sequencing and the TaqMan SNP Genotyping Assay are rapid and highly sensitive methods for detecting drug resistance in leprosy cases. The current study revealed that diamino-diphenylsulfone (DDS; also known as dapsone) resistance in M. leprae, as indicated by folP1 gene detection, is still the most concerning form of drug resistance in leprosy patients from Southwest China. Despite being a curable disease, leprosy remains a public health problem in more than 100 countries, where over 200,000 new leprosy cases are reported each year. The incidence rate has remained steady since 2005, indicating continued active transmission of the disease. Since the 1940s, the strategy for leprosy control has involved diamino-diphenylsulfone (DDS) monotherapy and then multidrug therapy (MDT), as recommended by the World Health Organization in 1982. After 30 years of DDS monotherapy, drug resistance has been described worldwide, and after 30 years of MDT, drug resistance has unsurprisingly been observed. However, the nature of drug resistance in Southwest China is still unknown. As the sensitivity of the PCR/sequencing method is limited, especially among paucibacillary (PB) patients, we developed a nested PCR/sequencing and TaqMan SNP Genotyping Assay that dramatically increased the sensitivity of detecting drug resistance among drug resistance-determining regions (DRDRs). According to results, the folP1 mutant is predominant, but rpoB mutants were not found. The results of this study indicate the preliminary characteristics of drug resistance in the DRDRs of leprosy patients from Southwest China.

31 October 2019 in Transactions of the Royal Society of Tropical Medicine and Hygiene
Verified
Journal Article
Open access
PDF file
LJLiu Jian
Liu Jian
SXShang Xiujian
Shang Xiujian
YYYou Yuangang
You Yuangang
XYXing Yan
Xing Yan
YLYuan Lianchao
Yuan Lianchao
WYWen Yan
Wen Yan
Although multidrug therapy (MDT) has been widely used for the treatment of leprosy for nearly 40 y, the disease remains a public health concern in some areas. The early detection of leprosy cases is vital to interrupt Mycobacterium leprae transmission, but currently diagnosis is typically achieved during the recognition of clinical symptoms by professional staff performing physical examinations in conjunction with microbiological assessment of slit skin smears (SSSs) and histopathology. In the last 10 y, serum antibody detection tests have emerged to aid leprosy diagnosis. Here we evaluated the ability of antigens NDO-BSA and LID-1 (ML0405 and ML2331) and the conjugate of these, NDO-LID, to detect antibodies in the sera of 113 leprosy patients and 166 control individuals in Yunnan province in southwest China. We found that each antigen was readily detected by sera from multibacillary (MB) patients, with sensitivities of 97.3%, 97.3% and 98.6% for NDO-BSA, LID-1 and NDO-LID, respectively. Even among paucibacillary (PB) patients the antigens detected antibodies in 74.4%, 56.4% and 69.2% of serum samples, respectively. Receiver operating characteristics (ROC) curve analysis indicated that, irrespective of the leprosy case classification as MB or PB, the detection efficiency obtained with NDO-LID was better than that obtained with the other two antigens (with LID-1 being a slightly better than NDO-BSA). Our results indicate the utility of NDO-LID in assisting in the diagnosis of PB and MB leprosy patients and that these antibody detection assays represent powerful diagnostic tools. We suggest that could be implemented into the procedures of local health centres in leprosy-endemic regions to assist in earlier diagnosis.

24 September 2018 in PLOS Neglected Tropical Diseases
Verified
Journal Article
Open access
PDF file
XCXiaohua Chen
Xiaohua Chen
YYYuan-Gang You
Yuan-Gang You
LYLian Chao Yuan
Lian Chao Yuan
YZYing Zhang
Ying Zhang
WYWen Yan
Wen Yan
To evaluate antigen-specific immune responses for leprosy diagnosis in a hyperendemic area in China. Eighty-three leprosy patients and 161 non-leprosy controls were enrolled from Hani-yi Autonomous Prefecture of Honghe, Yunnan Province, China. Leprosy patients were divided into multibacillary (MB, n = 38), paucibacillary (PB, n = 23), and post-multi-drug therapy (MDT, n = 22) groups. Controls were divided into the following groups: healthy household contacts (HHC, n = 119), tuberculosis (TB, n = 11), and endemic controls (EC, n = 31). The NDO-LID Rapid Test, M. leprae antigen-specific ELISA and antigen-specific IFN-γ secretion in a whole blood assay (WBA) were used to evaluate these subjects. The NDO-LID Rapid Test achieved higher positive response rates in MB than in PB patients[94.7%(36/38) vs 65.2%(15/23)], and these rates were higher than those observed by ELISA using anti-LID-1[92.1%(35/38) vs 52.2%(12/23)], anti-NDO-LID[92.1%(35/38) vs 47.8% (11/23)], and anti-ND-O-BSA[89.5%(34/38) vs 60.9%(14/23)]. However, the NDO-LID Rapid Test also showed a higher positive response rate in the EC group (33.3%,10/31), which was higher than the rates observed for anti-NDO-LID (12.9%,4/31) and anti-ND-O-BSA (16.1%,5/31). M. leprae antigen-specific ELISA demonstrated relatively high specificity (86.84–97.37%) but low sensitivity (15.97–72.73%) in discriminating between leprosy patients and non-leprosy controls by ROC curve analysis. In contrast, M. leprae antigen-specific IFN-γ secretion detection achieved higher positive response rates in PB than in MB patients (positive ratio of MB vs PB: 40% vs 56% for LID-1, 28.6% vs 47.8% for ML89, 31.4% vs 60.7% for ML2044, and 31.4 vs 47.8% for ML2028) and could distinguish MB from EC when stimulated with ML89(AUC = 0.6664) and PB fromTB when stimulated with ML2044 and ML2028(AUC = 0.7549 and 0.7372, respectively). The NDO-LID Rapid Test and M. leprae antigen-specific ELISA are useful tools to assist in the diagnosis of leprosy patients, especially MB patients, although the former had higher sensitivity but lower specificity than the latter. M. leprae antigen-specific IFN-γ release assessed by WBA has diagnostic value for distinguishing PB from TB but not for distinguishing PB from HHC or EC. Screening novel M. leprae-specific antigens, combining different M. leprae antigens and a multi-cytokine analyte model may be needed for more effective diagnosis of leprosy. Although the implementation of World Health Organization (WHO) multidrug therapy (MDT) treatment has drastically reduced the number of registered leprosy cases, new case detection rates have stabilized over the last decade, and leprosy remains an important health problem in many regions. Antigen-specific immune diagnostic tools are helpful for leprosy diagnosis but require broad evaluation in different populations from areas with hyperendemic leprosy. The NDO-LID Rapid Test, M. leprae antigen-specific ELISA and antigen-specific secretion of IFN-γ in a whole blood assay (WBA) can be used to diagnose multibacillary (MB) and paucibacillary (PB) leprosy patients. The authors found that in Honghe Autonomous Prefecture,Yunnan Province, China, the NDO-LID Rapid Test and M. leprae antigen-specific ELISA have the potential to be used as tools to assist in the diagnosis of patients with MB leprosy. The NDO-LID Rapid Test has higher sensitivity but lower specificity than the M. leprae antigen-specific ELISA. M. leprae antigen-specific IFN-γ secretion in WBA exhibited diagnostic value for distinguishing PB from TB but not for distinguishing PB from HHC or EC. This study provides an evaluation of antigen-specific immune responses for leprosy diagnosis in a hyperendemic area in China.

17 May 2018 in Scientific Reports
Verified
Journal Article
Open access
PDF file
XCXiaohua Chen
Xiaohua Chen
LZLiangfu Zhang
Liangfu Zhang
MHMeiying Huang
Meiying Huang
XZXiuli Zhai
Xiuli Zhai
YWYan Wen
Yan Wen
CPChunzhi Pan
Chunzhi Pan
The purpose of this study was to evaluate peripheral neural impairment in leprosy patients by ultrasonography (US). The cross-sectional areas (CSAs) of the median (M), ulnar (U) and common fibular (CF) nerves were compared in 71 leprosy patients and 29 healthy controls, and the data were analyzed between the leprosy, multibacillary (MB)/paucibacillary (PB), reaction (R)/no reaction (NR), disability (D)/no disability (ND), and longer/shorter duration groups after treatment. We found that for the nerves located in upper limbs, the CSAs were significantly increased in the leprosy patients vs the controls; the PB group vs the MB group; the R group vs the NR group; the ND group vs the D group; and the longer duration group vs the shorter duration group at some positions of the M nerve and U nerve. In contrast, for the nerves located in lower limbs, the CSAs were significantly reduced in the leprosy patients vs the controls and in the longer duration group vs the shorter duration group at some positions of the CF nerve. This result indicated that nerve enlargement and neuratrophy coexist in leprosy patients.

2 October 2019 in PLOS Neglected Tropical Diseases
Verified
Journal Article
Open access
PDF file
XCXiaohua Chen
Xiaohua Chen
YXYan Xing
Yan Xing
JHJun He
Jun He
FTFuyue Tan
Fuyue Tan
YYYuangang You
Yuangang You
YWYan Wen
Yan Wen
Detection and pathology analysis of Mycobacterium leprae using skin biopsy tissues are essential for leprosy diagnosis and monitoring response to treatment. Although formalin fixation of patient tissues may not be ideal for molecular studies, biopsy samples are the most accessible material from suspected cases. Therefore, clinical molecular laboratories must be able to utilize formalin-fixed, paraffin-embedded (FFPE) material. To determine the best molecular method for diagnosing and monitoring leprosy in FFPE specimens, we developed a single-tube nested PCR (STNPCR) (131 bp) and SYBRGreen PCR (101 bp) assay using primers for the M. leprae-specific repetitive element (RLEP) gene and evaluated the results compared to those using previously established RLEP primers (372 bp). FFPE biopsy samples obtained from 145 leprosy patients (during or after multidrug therapy (MDT)) and patients with 29 other confounding dermatoses were examined by the bacteria index (BI) and by simple PCR, STNPCR, and SYBRGreen PCR using primers amplifying a 372-bp, 131-bp or 101-bp fragment of RLEP, respectively. In leprosy patients receiving MDT, STNPCR showed a highest specificity of 100% and a positive predictive value (PPV) of 100%. For multibacillary (MB), paucibacillary (PB) and all leprosy patients, the highest sensitivities were 91.42%, 39.13%, and 67.92%, negative predictive values (NPVs) were 8.57%, 60.36%, and 32.07%, and the highest accuracies were 93.93%, 62.67%, and 74.81%, respectively, higher than the results of SYBRGreen PCR and simple PCR. For post-MDT leprosy patients, SYBRGreen PCR showed the highest sensitivity of 50.0%, highest specificity of 100%, a PPV of 100%, an NPV of 100% and the highest accuracy of 83.72% for MB patients, which were higher than those of STNPCR and simple PCR. STNPCR showed the highest sensitivity of 26.66% and 34.48%, highest specificity of 100% and 100%, a PPV of 100% and 100%, NPV of 72.50% and 60.21%, and highest accuracy of 75.00% and 67.24% for PB and leprosy patients, respectively, higher than those of SYBRGreen PCR and simple PCR. These findings suggest that STNPCR or SYBRGreen PCR (131-bp and 101-bp fragment amplification, respectively) for RLEP using FFPE specimens performs better as a diagnostic test and for monitoring response to MDT than does simple PCR based on 372-bp fragment amplification. Additionally, STNPCR showed increased sensitivity for PB diagnosis using FFPE specimens, which can be transferred remotely or retrieved from previous leprosy patients. Leprosy is one of the oldest diseases known to humankind and is caused by Mycobacterium leprae. Despite being curable, leprosy is still a notorious disease, causing serious disability and a stigma generally associated with late diagnosis. The disease is challenging to diagnose because there is no gold standard method for detecting M. leprae or its cellular components (DNA, lipids or proteins). In past decades, different PCR methods were developed to amplify different M. leprae gene targets, such as the RLEP gene, with high sensitivity in leprosy diagnosis using skin biopsy and slit skin smear (SSS) specimens. However, few reports have focused on FFPE specimens. Because FFPE specimens can be transferred remotely or retrieved from previous leprosy patients, we developed and evaluated the STNPCR assay for detecting M. leprae in these specimens. Our results suggest that STNPCR of RLEP using FFPE specimens performs better as a diagnostic test and for monitoring response to MDT than does simple PCR.